These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22448395)

  • 1. [GMP production.Shaping the future].
    Wester HJ
    Nuklearmedizin; 2012; 51(1):N1-4. PubMed ID: 22448395
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nuclear oncology 2000: the end of individualized professionalism].
    Carrio I
    Rev Esp Med Nucl; 2000 Jun; 19(3):179-81. PubMed ID: 11062079
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiopharmaceutical research and production in Brazil: a 30-year history of participation in the nuclear medicine scenario.
    Santos-Oliveira R; Antunes LJ
    J Nucl Med Technol; 2011 Sep; 39(3):237-9. PubMed ID: 21795367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines--child's play or a practical minefield?
    Nucl Med Commun; 2007 Jul; 28(7):583. PubMed ID: 17538401
    [No Abstract]   [Full Text] [Related]  

  • 5. [Nuclear medicine entangled by administrative regulations].
    Meyer GJ
    Nuklearmedizin; 2013; 52(2):N11-5. PubMed ID: 23503760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The profession and the industry: friends and foes.
    Ell PJ
    Eur J Nucl Med; 1998 Nov; 25(11):1472-4. PubMed ID: 9882184
    [No Abstract]   [Full Text] [Related]  

  • 7. The industry and the profession: friends or foes?
    Jeans J; Vermeeren P
    Eur J Nucl Med; 1998 Nov; 25(11):1469-71. PubMed ID: 9882183
    [No Abstract]   [Full Text] [Related]  

  • 8. Instrumentation and radiopharmaceutical validation.
    Zigler SS
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future of nuclear medicine, part 3: assessment of the U.S. therapeutic radiopharmaceuticals market (2001-2020).
    J Nucl Med; 1998 Jul; 39(7):14N, 17N-18N, 20N-22N, 25N, 27N. PubMed ID: 9669377
    [No Abstract]   [Full Text] [Related]  

  • 10. Future of nuclear medicine, part 1: marketing research forecasts.
    J Nucl Med; 1998 Feb; 39(2):27N-30N. PubMed ID: 9476920
    [No Abstract]   [Full Text] [Related]  

  • 11. About mentioning quality of preparation and quality control of radiopharmaceuticals used in nuclear medicine procedures.
    Wozniak G; Georgoulias P; Archimandritis S; Dimakopoulos N; Fezoulidis I
    Hell J Nucl Med; 2006; 9(1):41-2. PubMed ID: 16617394
    [No Abstract]   [Full Text] [Related]  

  • 12. [Shaping the future together].
    Adam G; Forsting M; Bockisch A; Kotzerke J
    Rofo; 2012 Apr; 184(4):301-2. PubMed ID: 22426866
    [No Abstract]   [Full Text] [Related]  

  • 13. Exemption of radiopharmaceuticals from <797>.
    Hung JC; VanBrocklin HF
    J Nucl Med; 2004 Oct; 45(10):14N. PubMed ID: 15551510
    [No Abstract]   [Full Text] [Related]  

  • 14. [On the situation of permit free self-production of radiopharmaceuticals in nuclear medicine].
    Hoppe U; Machulla HJ; Neumaier B
    Nuklearmedizin; 2013; 52(5):N53-4. PubMed ID: 24085459
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiopharmaceutical space.
    Eckelman WC; Kilbourn MR; Mathis CA
    Nucl Med Biol; 2006 Oct; 33(7):829. PubMed ID: 17045161
    [No Abstract]   [Full Text] [Related]  

  • 16. From the SNM Committee on Pharmacopeia: Exemption of radiopharmaceuticals from <797>.
    Hung JC;
    J Nucl Med; 2004 Oct; 45(10):13N, 16N. PubMed ID: 15551509
    [No Abstract]   [Full Text] [Related]  

  • 17. Future of nuclear medicine, part 2: assessment of the U.S. diagnostic radio-pharmaceuticals market (2001-2020).
    J Nucl Med; 1998 Mar; 39(3):20N, 22N-25N. PubMed ID: 9529277
    [No Abstract]   [Full Text] [Related]  

  • 18. Procedure guideline for the use of radiopharmaceuticals 4.0.
    Callahan RJ; Chilton HM; Ponto JA; Swanson DP; Royal HD; Bruce AD
    J Nucl Med Technol; 2007 Dec; 35(4):272-5. PubMed ID: 18006598
    [No Abstract]   [Full Text] [Related]  

  • 19. Communicating across the boundaries.
    Duatti A; Smith SV
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):245-7. PubMed ID: 17043622
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiopharmaceutical providers to continue growth.
    Thompson CA
    Am J Hosp Pharm; 1993 Apr; 50(4):582-3. PubMed ID: 8470671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.